Send to

Choose Destination
Curr Med Res Opin. 2003;19(6):470-2.

The evolving role of telomerase inhibitors in the treatment of cancer.

Author information

Institute of Cancer Genetics and Pharmacogenomics, Brunel University, and St George's and the Princess Grace Hospitals, London, UK.


Telomerase is a ribonucleoprotein that maintains telomeres and is essential for cellular immortality and tumour growth. The differential expression of telomerase in cancer cells makes it an attractive therapeutic target. Anti-sense oligonucleotides directed against the RNA template of hTR and small molecules that can interact and stabilise the G-quadruplex represent promising therapeutic strategies. Human trials investigating the potential role of the catalytic subunit hTERT as a universal cancer vaccine have already commenced. Alternative lengthening of telomeres (ALT) and efficacy delay remain important limitations to anti-telomerase therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center